Cardiovascular Disease

Prorenone (SC 23133) is a spironolactone-type steroidal mineralocorticoid receptor (MR) antagonist that can cross the blood-brain barrier, with low affinity for glucocorticoid receptors and rat prostate androgen receptors. Prorenone inhibits the binding and action of Aldosterone (HY-113313), blocks its induced nuclear receptor activity and stimulated sodium transport, antagonizes aldosterone-induced urinary potassium excretion, and prevents aldosterone-induced elevation of blood pressure. Prorenone can be used in research related to hypertension.

Captopril-¹³C₅,¹⁵N (SQ 14225-¹³C₅,¹⁵N) is ¹³C and ¹⁵N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC₅₀=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC₅₀ of 7.9 μM.

Luminacin G2 has a strong inhibitory effect on capillary formation (IC₅₀ is less than 0.1 μg/mL).

Narvesiran is a notch-regulated ankyrin repeat protein (NRARP) synthesis reducer, angiogenesis inhibitor.

(3R,5R)-Rosuvastatin is a hERG potassium channel blocker and HMG-CoA reductase inhibitor that prolongs the action potential duration and QT interval by accelerating channel inactivation, impairing channel folding, reducing hERG mRNA transcription, and promoting the degradation of mature and immature hERG channels. (3R,5R)-Rosuvastatin can be used for research on long QT syndrome.

PHD2-IN-3 (compound 2) is a PHD2 inhibitor. PHD2-IN-3 can be used for study of anemia.

Pyrazole N-Desmethyl sildenafil (Compound 10) is an analog of Sildenafil (HY-15025). Pyrazole N-Desmethyl sildenafil shows 16% inhibition on Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) with 100 µM.

BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research.

ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke.

Sibrafiban (Standard) is the analytical standard of Sibrafiban. This product is intended for research and analytical applications. Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.

Colterol hydrochloride is the hydrochloride salt form of Colterol (HY-128510). Colterol hydrochloride is the agonist for adrenergic receptor, and exhibits good affinity to β1-adrenoreceptor (heart) and β2-adrenoreceptor (lung) with IC₅₀ of 645 nM and 147 nM. Colterol hydrochloride exhibits potential as a bronchodilator.

RU 752 is a potent mineralocorticoid receptors (type I or MR) antagonist.

SST1 receptor antagonist-2 (Example 2) is a piperazine derivative and a somatostatin receptor 1 (SST1) antagonist. SST1 receptor antagonist-2 can be used in the research of psychiatric diseases, neurodegenerative diseases, tumors, as well as vascular disorders and immunological diseases.

Febuxostat-d₃ (TEI 6720-d₃) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.

(R,S)-Norcotinine ((Rac)-Norcotinine) is the racemic mixture of Norcotinine. (R,S)-Norcotinine is a biomarker of secondhand smoke exposure and is associated with the toxic mechanisms of secondhand smoke on cardiovascular development.

Cotinine (Standard) is the analytical standard of Cotinine. This product is intended for research and analytical applications. Cotinine ((-)-Cotinine), an alkaloid in tobacco and a major metabolite of nicotine, is used as a biological indicator to measure the composition of tobacco smoke

Meglumine cyclic adenylate is a cAMP analog. Meglumine cyclic adenylate promotes STAT3 phosphorylation at Ser727 and mitochondrial translocation. Meglumine cyclic adenylate inhibits cell apoptosis by reducing cytochrome c release and caspase-3 activation. Meglumine cyclic adenylate suppresses the expression of NF-κBp65, activates adenylate cyclase 3, and inhibits phosphodiesterase 4D. Meglumine cyclic adenylate enhances myocardial contractility, increases myocardial Ca²⁺ influx, dilates peripheral blood vessels, improves hypotension and bradycardia, promotes spinal cord function recovery, and regulates fear extinction and anxiety-like behaviors. Meglumine cyclic adenylate can be used in research related to cerebral ischemia/reperfusion injury, systemic inflammatory response syndrome, acute T4 thoracic spinal cord injury, and post-traumatic stress disorder (PTSD).

(Rac)-BX 048 is a BX 048 racemate. BX 048 is a P2Y12 receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC₅₀ of 15 μM).

GYKI-14451 sulfate is an inhibitor of thrombin and plasmin. GYKI-14451 sulfate inhibits thrombin-fibrinogen and plasmin-fibrin reactions. GYKI-14451 sulfate inhibits fibrin clot lysis and prolongs fibrin clot lysis time in a dose-dependent manner. GYKI-14451 sulfate does not undergo N-terminal cyclization and spontaneous inactivation in neutral aqueous buffer. GYKI-14451 sulfate can be used in studies related to venous thrombosis and fibrinogen solidification.

Baslisiran is an angiotensinogen (AGT) synthesis inhibitor that can be used in studies related to hypertension.